BP is always is looking - they are hungry for new stream of revenues.
The top 2 targets are ALZ and NASH - they cannot be cured so lifetime requirements, huge patient population and no current treatments.
If the results are good to very good, BP can try acquiring early - even if P3 is required
See this - ‘Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle’ This company has one cancer drug - the market cap is already $5.3 B and they are saying MRK can buy at $8-10 B